Screener
Revolution Medicines, Inc. RVMD Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-208969
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $343,970 | $205,749 |
| General and administrative | 101,252 | 35,011 |
| Total operating expenses | 445,222 | 240,760 |
| Loss from operations | (445,222) | (240,760) |
| Non-operating income (expense), net: | ||
| Interest income | 19,508 | 24,915 |
| Interest expense | (12,197) | — |
Item 1. Financial Statements.
FAQ
- What is Revolution Medicines, Inc.'s total operating expenses?
- Revolution Medicines, Inc. (RVMD) reported total operating expenses of $445.22M in Q1 2026.
- How has Revolution Medicines, Inc.'s total operating expenses changed year-over-year?
- Revolution Medicines, Inc.'s total operating expenses increased by 84.9% year-over-year, from $240.76M to $445.22M.
- What is the long-term trend for Revolution Medicines, Inc.'s total operating expenses?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s total operating expenses has grown at a 52.7% compound annual growth rate (CAGR), from $217.4M to $1.18B.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Revolution Medicines, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude